- LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone - LV UNO compares ...
When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results